Advertisement

Cannabis Use: Neurobiological, Behavioral, and Sex/Gender Considerations

  • Anahita Bassir Nia
  • Claire Mann
  • Harsimar Kaur
  • Mohini Ranganathan
Addictions (M Potenza and M Brand, Section Editors)
  • 13 Downloads
Part of the following topical collections:
  1. Topical Collection on Addictions

Abstract

Purpose of Review

To summarize the current literature on the effects of cannabinoids in humans and to discuss the existing literature on the sex- and gender-related differences in the effects of cannabinoids.

Recent Findings

Cannabis and its constituent cannabinoids are associated with risk of addiction, cognitive deficits, and mood/psychotic disorders. Preclinical and emerging clinical data suggest greater sensitivity to the effects of cannabinoids in women.

Summary

Cannabis is one of the most commonly used drugs with increasing rates of use. Women in particular may be at a greater risk of adverse outcomes given the previously described “telescoping effect” of substance use in women. Human data examining the sex- and gender-related differences in the effects of cannabinoids and factors underlying these differences are very limited. This represents a critical gap in the literature and needs to be systematically examined in future studies.

Keywords

Cannabis Delta-9-tetrahydrocannabinol THC Sex differences Gender Endocannabinoid 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Ranganathan reports grants from Insys Therapeutics, outside the submitted work. Dr. Bassir Nia, Dr. Mann, and Dr. Kaur do not have anything to disclose.

Human and Animal Rights

All cited studies/experiments with human or animal subjects have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Supplementary material

40473_2018_167_MOESM1_ESM.docx (38 kb)
ESM 1 (DOCX 37.6 kb)

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Center for Behavioral Health Statistics and Quality. (2017). 2016 National survey on drug use and health: detailed tables. Substance abuse and mental health services administration, Rockville, MD.Google Scholar
  2. 2.
    Zakiniaeiz Y, Cosgrove KP, Potenza MN, Mazure CM. Balance of the sexes: addressing sex differences in preclinical research. Yale J Biol Med. 2016;89(2):255–9.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Chapman C, Slade T, Swift W, Keyes K, Tonks Z, Teesson M. Evidence for sex convergence in prevalence of cannabis use: a systematic review and meta-regression. J Stud Alcohol Drugs. 2017;78(3):344–52.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Johnson RM, Fairman B, Gilreath T, Xuan Z, Rothman EF, Parnham T, et al. Past 15-year trends in adolescent marijuana use: differences by race/ethnicity and sex. Drug Alcohol Depend. 2015;155:8–15.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Substance Abuse and Mental Health Services Administration. (2007). Results from the 2006 national Survey on drug use and health: National findings (Office of Applied Studies, N.S.H.)Google Scholar
  6. 6.
    Pacek LR, Mauro PM, Martins SS. Perceived risk of regular cannabis use in the United States from 2002 to 2012: differences by sex, age, and race/ethnicity. Drug Alcohol Depend. 2015;149:232–44.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Leghissa A, Hildenbrand ZL, Schug KA. A review of methods for the chemical characterization of cannabis natural products. J Sep Sci. 2018;41(1):398–415.PubMedCrossRefGoogle Scholar
  8. 8.
    Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178(2):101–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Zuardi A et al (2017). The anxiolytic effects of cannabidiol (CBD), in Handbook of Cannabis and Related Pathologies. , Elsevier. p. e131-e139Google Scholar
  10. 10.
    O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70:341–8.PubMedCrossRefGoogle Scholar
  11. 11.
    McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatr. 2018;175(3):225–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Administration U.S.F.A.D. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA News ReleaseGoogle Scholar
  13. 13.
    Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–64.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Sloan ME, Gowin JL, Ramchandani VA, Hurd YL, le Foll B. The endocannabinoid system as a target for addiction treatment: trials and tribulations. Neuropharmacology. 2017;124:73–83.PubMedCrossRefGoogle Scholar
  15. 15.
    Parsons LH, Hurd YL. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci. 2015;16(10):579–94.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Grotenhermen F. Pharmacology of cannabinoids. Neuro Endocrinol Lett. 2004;25(1–2):14–23.PubMedGoogle Scholar
  17. 17.
    Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, et al. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology. 2013;226(2):401–13.PubMedCrossRefGoogle Scholar
  18. 18.
    D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology. 2008;33(10):2505–16.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    D'Souza DC, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology. 2008;198(4):587–603.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015;40(11):2489–98.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Ramesh D, Haney M, Cooper ZD. Marijuana's dose-dependent effects in daily marijuana smokers. Exp Clin Psychopharmacol. 2013;21(4):287–93.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology. 2003;166(1):77–85.PubMedCrossRefGoogle Scholar
  24. 24.
    • Cooper ZD and Haney M, Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend, 2014;136:85–91. This is a study demonstrating that women endorse greater cannabis-induced subjective effects suggestive of abuse liability compared to men.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol. 2013;18(5):872–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Kowal MA, van Steenbergen H, Colzato LS, Hazekamp A, van der Wee NJA, Manai M, et al. Dose-dependent effects of cannabis on the neural correlates of error monitoring in frequent cannabis users. Eur Neuropsychopharmacol. 2015;25(11):1943–53.PubMedCrossRefGoogle Scholar
  27. 27.
    • Boggs DL, et al. Clinical and preclinical evidence for functional interactions of cannabidiol and delta(9)-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142–54 This is a comprehensive review of preclinical and clinical data on the interactive effects of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). PubMedCrossRefGoogle Scholar
  28. 28.
    Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJA, et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol. 2015;25(3):325–34.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology. 2016;41(8):1974–82.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35(9):1879–85.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Tunbridge EM, Dunn G, Murray RM, Evans N, Lister R, Stumpenhorst K, et al. Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of delta9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences. J Psychopharmacol. 2015;29(11):1146–51.PubMedCrossRefGoogle Scholar
  32. 32.
    • Sherif M, et al. Human laboratory studies on cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):526–38 A comprehensive review of the acute effects of delta-9-tetrahydrocannabinol (THC) in humans from human laboratory studies. PubMedCrossRefGoogle Scholar
  33. 33.
    Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, et al. The psychosis-like effects of delta-tetrahydrocannabinol are associated with increased cortical noise in healthy humans. Biol Psychiatry. 2015;78:805–13.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    D'Souza DC, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594–608.PubMedCrossRefGoogle Scholar
  35. 35.
    Mason O, Morgan CJA, Dhiman SK, Patel A, Parti N, Patel A, et al. Acute cannabis use causes increased psychotomimetic experiences in individuals prone to psychosis. Psychol Med. 2009;39(6):951–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Mason OJ, Morgan CJM, Stefanovic A, Curran HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res. 2008;103(1–3):138–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Van der Veer N, Friday J. Persistent psychosis following the use of spice. Schizophr Res. 2011;130(1–3):285–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30(12):1321–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Max Spaderna PA, D'Souza D Spicing things up: the effects of synthetic cannabinoids. (2013: resubmitted).Google Scholar
  41. 41.
    Broyd SJ, van Hell HH, Beale C, Yücel M, Solowij N. Acute and chronic effects of cannabinoids on human cognition—a systematic review. Biol Psychiatry. 2016;79(7):557–67.PubMedCrossRefGoogle Scholar
  42. 42.
    • Crane NA, et al. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23(2):117–37 A review of the acute and non-acute effects of cannabis on neurocognition with emphasis on neurodevelopmental issues and sex/gender differences. PubMedCrossRefGoogle Scholar
  43. 43.
    Ranganathan M, D'Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188:425–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boorman M, et al. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. Accid Anal Prev. 2013;50:879–86.PubMedCrossRefGoogle Scholar
  45. 45.
    Lenne MG, et al. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev. 2010;42(3):859–66.PubMedCrossRefGoogle Scholar
  46. 46.
    Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving lateral control with and without alcohol. Drug Alcohol Depend. 2015;154:25–37.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, et al. Cannabis effects on driving longitudinal control with and without alcohol. J Appl Toxicol. 2016;36(11):1418–29.PubMedCrossRefGoogle Scholar
  48. 48.
    Arria AM, Wilcox HC, Caldeira KM, Vincent KB, Garnier-Dykstra LM, O'Grady KE. Dispelling the myth of “smart drugs”: cannabis and alcohol use problems predict nonmedical use of prescription stimulants for studying. Addict Behav. 2013;38(3):1643–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Ranganathan M, Skosnik PD, D'Souza DC. Marijuana and madness: associations between cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):511–3.PubMedCrossRefGoogle Scholar
  50. 50.
    Chadi N, Levy S, Radhakrishnan R, Ranganathan M, Weiner ASB. Introduction. In: Winters KCSKC, Kevin A, editors. Contemporary health issues on marijuana. Oxford: Oxford University Press; 2018.Google Scholar
  51. 51.
    Marwaha S, Winsper C, Bebbington P, Smith D. Cannabis use and hypomania in young people: a prospective analysis. Schizophr Bull. 2018;44(6):1267–274.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Duperrouzel J, et al. The association between adolescent cannabis use and anxiety: a parallel process analysis. Addict Behav. 2017;78:107–13.PubMedCrossRefGoogle Scholar
  53. 53.
    Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav. 2014;39(5):994–9.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    McHale S, Hunt N. Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol. 2008;23(5):409–15.PubMedCrossRefGoogle Scholar
  55. 55.
    Pope HG Jr, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909–15.PubMedCrossRefGoogle Scholar
  56. 56.
    Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana--a comparison with pre-drug performance. Neurotoxicol Teratol. 2005;27(2):231–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Meier MH et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci, 2012;109(40):E2657–64.CrossRefGoogle Scholar
  58. 58.
    Melchior M, Bolze C, Fombonne E, Surkan PJ, Pryor L, Jauffret-Roustide M. Early cannabis initiation and educational attainment: is the association causal? Data from the French TEMPO study. Int J Epidemiol. 2017;46(5):1641–50.PubMedCrossRefGoogle Scholar
  59. 59.
    Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch health and development study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317–26.PubMedCrossRefGoogle Scholar
  60. 60.
    Meier MH, Hill ML, Small PJ, Luthar SS. Associations of adolescent cannabis use with academic performance and mental health: a longitudinal study of upper middle class youth. Drug Alcohol Depend. 2015;156:207–12.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Homel J, Thompson K, Leadbeater B. Trajectories of marijuana use in youth ages 15-25: implications for postsecondary education experiences. J Stud Alcohol Drugs. 2014;75(4):674–83.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Rodwell L et al. Adolescent mental health and behavioural predictors of being NEET: a prospective study of young adults not in employment, education, or training. Psychol Med. 2018;48(5):861–71.PubMedCrossRefGoogle Scholar
  63. 63.
    D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):413–31.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21(2):152–62.PubMedCrossRefGoogle Scholar
  65. 65.
    Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39–47.PubMedCrossRefGoogle Scholar
  66. 66.
    Marconi A, di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262–9.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Allegri F, Belvederi Murri M, Paparelli A, Marcacci T, Braca M, Menchetti M, et al. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013;210(1):368–70.PubMedCrossRefGoogle Scholar
  68. 68.
    Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555–61.PubMedCrossRefGoogle Scholar
  69. 69.
    Myles N, Newall H, Nielssen O, Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des. 2012;18(32):5055–69.PubMedCrossRefGoogle Scholar
  70. 70.
    Di Forti M, et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 2014;40(6):1509–17.PubMedCrossRefGoogle Scholar
  71. 71.
    Walsh Z, Gonzalez R, Crosby K, S. Thiessen M, Carroll C, Bonn-Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15–29.PubMedCrossRefGoogle Scholar
  72. 72.
    O'neil ME, et al. Benefits and harms of plant-based cannabis for posttraumatic stress disorder: a systematic review. Ann Intern Med. 2017;167(5):332–40.PubMedCrossRefGoogle Scholar
  73. 73.
    Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. PLoS One. 2013;8(10):e76635.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol. 2007;152(5):795–804.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Fattore L, Spano MS, Altea S, Fadda P, Fratta W. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol. 2010;160(3):724–35.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Tseng AH, Craft RM. CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats. Psychopharmacology. 2004;172(1):25–30.PubMedCrossRefGoogle Scholar
  77. 77.
    Tseng AH, Craft RM. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol. 2001;430(1):41–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Craft RM, Kandasamy R, Davis SM. Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Delta(9)-tetrahydrocannabinol in the rat. Pain. 2013;154(9):1709–17.PubMedCrossRefGoogle Scholar
  79. 79.
    Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8–9):476–81.PubMedCrossRefGoogle Scholar
  80. 80.
    Harte-Hargrove LC, Dow-Edwards DL. Withdrawal from THC during adolescence: sex differences in locomotor activity and anxiety. Behav Brain Res. 2012;231(1):48–59.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Wiley JL. Sex-dependent effects of delta 9-tetrahydrocannabinol on locomotor activity in mice. Neurosci Lett. 2003;352(2):77–80.PubMedCrossRefGoogle Scholar
  82. 82.
    Wakley AA, Wiley JL, Craft RM. Sex differences in antinociceptive tolerance to delta-9-tetrahydrocannabinol in the rat. Drug Alcohol Depend. 2014;143:22–8.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Wakley AA, Wiley JL, Craft RM. Gonadal hormones do not alter the development of antinociceptive tolerance to delta-9-tetrahydrocannabinol in adult rats. Pharmacol Biochem Behav. 2015;133:111–21.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Cha YM, Jones KH, Kuhn CM, Wilson WA, Swartzwelder HS. Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol. 2007;18(5–6):563–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Cocchetto DM, Owens SM, Perez-Reyes M, DiGuiseppi S, Miller LL. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology. 1981;75(2):158–64.PubMedCrossRefGoogle Scholar
  86. 86.
    Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003;75(2):309–18.PubMedCrossRefGoogle Scholar
  87. 87.
    Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD. Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, Healthy Adults. Neuropsychopharmacology. 2006;31(2):462–70.PubMedCrossRefGoogle Scholar
  88. 88.
    Fogel JS, Kelly TH, Westgate PM, Lile JA. Sex differences in the subjective effects of oral delta(9)-THC in cannabis users. Pharmacol Biochem Behav. 2017;152:44–51.PubMedCrossRefGoogle Scholar
  89. 89.
    Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend. 2009;103(3):107–13.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology. 2007;32(6):1391–403.PubMedCrossRefGoogle Scholar
  91. 91.
    Penetar DM, Kouri EM, Gross MM, McCarthy EM, Rhee CK, Peters EN, et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend. 2005;79(2):211–23.PubMedCrossRefGoogle Scholar
  92. 92.
    Anderson BM, Rizzo M, Block RI, Pearlson GD, O'Leary DS. Sex, drugs, and cognition: effects of marijuana. J Psychoactive Drugs. 2010;42(4):413–24.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Grant JD, Scherrer JF, Neuman RJ, Todorov AA, Price RK, Bucholz KK. A comparison of the latent class structure of cannabis problems among adult men and women who have used cannabis repeatedly. Addiction. 2006;101(8):1133–42.PubMedCrossRefGoogle Scholar
  94. 94.
    • Herrmann ES, Weerts EM, Vandrey R. Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. Exp Clin Psychopharmacol. 2015;23(6):415–21 This study demonstrates more severe symptoms of cannabis withdrawal in women compared to men. PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Cuttler C, Mischley LK, Sexton M. Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users. Cannabis Cannabinoid Res. 2016;1(1):166–75.PubMedPubMedCentralCrossRefGoogle Scholar
  96. 96.
    Noack R, Hofler M, Lueken U. Cannabis use patterns and their association with DSM-IV cannabis dependence and gender. Eur Addict Res. 2011;17(6):321–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Schlienz NJ, Budney AJ, Lee DC, Vandrey R. Cannabis withdrawal: a review of neurobiological mechanisms and sex differences. Curr Addict Rep. 2017;4(2):75–81.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Sherman BJ, McRae-Clark AL, Baker NL, Sonne SC, Killeen TK, Cloud K, et al. Gender differences among treatment-seeking adults with cannabis use disorder: clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study. Am J Addict. 2017;26(2):136–44.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Copersino ML, Boyd SJ, Tashkin DP, Huestis MA, Heishman SJ, Dermand JC, et al. Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse. 2010;36(6):311–9.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Agrawal A, Lynskey MT, Madden PAF, Pergadia ML, Bucholz KK, Heath AC. Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend. 2009;101(1–2):8–12.PubMedCrossRefGoogle Scholar
  101. 101.
    • Khan SS, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2013;130(1-3):101–8 Data from a large national sample demonstrating telescoping phenomenon in women with cannabis use. PubMedCrossRefGoogle Scholar
  102. 102.
    Ehlers CL, Gizer IR, Vieten C, Gilder DA, Stouffer GM, Lau P, et al. Cannabis dependence in the San Francisco family study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35(2):102–10.PubMedCrossRefGoogle Scholar
  103. 103.
    Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265–72.PubMedCrossRefGoogle Scholar
  104. 104.
    McDonald J, Schleifer L, Richards JB, de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology. 2003;28(7):1356–65.PubMedCrossRefGoogle Scholar
  105. 105.
    Roser P, Gallinat J, Weinberg G, Juckel G, Gorynia I, Stadelmann AM. Psychomotor performance in relation to acute oral administration of delta9-tetrahydrocannabinol and standardized cannabis extract in healthy human subjects. Eur Arch Psychiatry Clin Neurosci. 2009;259(5):284–92.PubMedCrossRefGoogle Scholar
  106. 106.
    Pope HG Jr, et al. Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom. 1997;66(4):179–84.PubMedCrossRefGoogle Scholar
  107. 107.
    Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc. 2013;19(9):1009–15.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Crane NA, Schuster RM, Mermelstein RJ, Gonzalez R. Neuropsychological sex differences associated with age of initiated use among young adult cannabis users. J Clin Exp Neuropsychol. 2015;37(4):389–401.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Skosnik PD, et al. The effect of cannabis use and gender on the visual steady state evoked potential. Clin Neurophysiol. 2006;117(1):144–56.PubMedCrossRefGoogle Scholar
  110. 110.
    Eranti SV, MacCabe JH, Bundy H, Murray RM. Gender difference in age at onset of schizophrenia: a meta-analysis. Psychol Med. 2013;43(1):155–67.PubMedCrossRefGoogle Scholar
  111. 111.
    • Donoghue K, et al. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014;215(3):528–32 This study suggests that cannabis use is associated with earlier psychosis onset and the typical age differences between men and women diminishes in cannabis users.PubMedCrossRefGoogle Scholar
  112. 112.
    Compton MT, et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry. 2009;166(11):1251–7.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Decoster J, van Os J, Kenis G, Henquet C, Peuskens J, de Hert M, et al. Age at onset of psychotic disorder: cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(3):363–9.PubMedCrossRefGoogle Scholar
  114. 114.
    Foster KT, Li N, McClure EA, Sonne SC, Gray KM. Gender differences in internalizing symptoms and suicide risk among men and women seeking treatment for cannabis use disorder from late adolescence to middle adulthood. J Subst Abus Treat. 2016;66:16–22.CrossRefGoogle Scholar
  115. 115.
    Danielsson AK, Lundin A, Allebeck P, Agardh E. Cannabis use and psychological distress: an 8-year prospective population-based study among Swedish men and women. Addict Behav. 2016;59:18–23.PubMedCrossRefGoogle Scholar
  116. 116.
    Szutorisz H, Egervári G, Sperry J, Carter JM, Hurd YL. Cross-generational THC exposure alters the developmental sensitivity of ventral and dorsal striatal gene expression in male and female offspring. Neurotoxicol Teratol. 2016;58:107–14.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Kosty DB, Farmer RF, Seeley JR, Gau JM, Duncan SC, Lewinsohn PM. Parental transmission of risk for cannabis use disorders to offspring. Addiction. 2015;110(7):1110–7.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Cho BY. Associations of father’s lifetime cannabis use disorder with child’s initiation of cannabis use, alcohol use, and sexual intercourse by child gender. Subst Use Misuse. 2018;53(14):2330–8.PubMedCrossRefGoogle Scholar
  119. 119.
    Castelli MP et al. Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones. Curr Pharm Des, 2013.Google Scholar
  120. 120.
    Rubino T, Parolaro D. Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. Front Behav Neurosci. 2011;5:64.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Mateos B, Borcel E, Loriga R, Luesu W, Bini V, Llorente R, et al. Adolescent exposure to nicotine and/or the cannabinoid agonist CP 55,940 induces gender-dependent long-lasting memory impairments and changes in brain nicotinic and CB(1) cannabinoid receptors. J Psychopharmacol. 2011;25(12):1676–90.PubMedCrossRefGoogle Scholar
  122. 122.
    Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ. Regional enhancement of cannabinoid CB#8321; receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol. 2010;161(1):103–12.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Silva L, Black R, Michaelides M, Hurd YL, Dow-Edwards D. Sex and age specific effects of delta-9-tetrahydrocannabinol during the periadolescent period in the rat: the unique susceptibility of the prepubescent animal. Neurotoxicol Teratol. 2016;58:88–100.PubMedCrossRefGoogle Scholar
  124. 124.
    Alteba S, Korem N, Akirav I. Cannabinoids reverse the effects of early stress on neurocognitive performance in adulthood. Learn Mem. 2016;23(7):349–58.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Zamberletti E, Prini P, Speziali S, Gabaglio M, Solinas M, Parolaro D, et al. Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience. 2012;204:245–57.PubMedCrossRefGoogle Scholar
  126. 126.
    • Van Laere K, et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. NeuroImage. 2008;39(4):1533–41 A PET study demonstrating gender related differences in cannabinoid receptor availability in humans. PubMedCrossRefGoogle Scholar
  127. 127.
    • Normandin MD, et al. Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences. J Cereb Blood Flow Metab. 2015;35(8):1313–22 A PET study demonstrating gender-related differences in cannabinoid receptor availability in humans. PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H. Sex difference in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat. Biochem Pharmacol. 1991;41(8):1187–94.PubMedCrossRefGoogle Scholar
  129. 129.
    • Tseng AH, Harding JW, Craft RM. Pharmacokinetic factors in sex differences in delta 9-tetrahydrocannabinol-induced behavioral effects in rats. Behav Brain Res. 2004;154(1):77–83 This study identifies sex differences in the pharmacokinetics of cannabinoids using preclinical data. PubMedCrossRefGoogle Scholar
  130. 130.
    Wiley JL, Burston JJ. Sex differences in Delta(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats. Neurosci Lett. 2014;576:51–5.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Castelli MP, et al. Male and female rats differ in brain cannabinoid CB1 receptor density and function and in behavioural traits predisposing to drug addiction: effect of ovarian hormones. Curr Pharm Des. 2014;20(13):2100–13.PubMedCrossRefGoogle Scholar
  132. 132.
    Marusich JA, Craft RM, Lefever TW, Wiley JL. The impact of gonadal hormones on cannabinoid dependence. Exp Clin Psychopharmacol. 2015;23(4):206–16.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Anahita Bassir Nia
    • 1
  • Claire Mann
    • 2
  • Harsimar Kaur
    • 1
  • Mohini Ranganathan
    • 3
  1. 1.School of MedicineYale UniversityNew HavenUSA
  2. 2.Icahn School of Medicine at Mount SinaiNew YorkUSA
  3. 3.School of Medicine, VA Connecticut Healthcare SystemYale UniversityWest HavenUSA

Personalised recommendations